PlainRecalls
FDA Drug Moderate Class II Terminated

JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA

Reported: March 29, 2023 Initiated: March 9, 2023 #D-0468-2023

Product Description

JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA

Reason for Recall

Labeling: Label Mix-up

Details

Units Affected
69,375 bottles
Distribution
Product was distributed nationwide within the United States and PR
Location
Ridgefield, CT

Frequently Asked Questions

What product was recalled?
JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA. Recalled by Boehringer Ingelheim Pharmaceuticals, Inc.. Units affected: 69,375 bottles.
Why was this product recalled?
Labeling: Label Mix-up
Which agency issued this recall?
This recall was issued by the FDA Drug on March 29, 2023. Severity: Moderate. Recall number: D-0468-2023.